Goede V, Fischer K, Dyer MJS, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. EHA 2018; abstract S151.
‘Risicomodel IPSS-M dient standaard te worden gebruikt bij MDS’
okt 2023 | MDS, Stamceltransplantatie